Prosecution Insights
Last updated: April 19, 2026

Examiner: HANEY, AMANDA MARIE

Tech Center 1600 • Art Units: 1634 1682

This examiner grants 36% of resolved cases

Performance Statistics

36.5%
Allow Rate
-23.5% vs TC avg
759
Total Applications
+44.0%
Interview Lift
1305
Avg Prosecution Days
Based on 702 resolved cases, 2023–2026

Rejection Statute Breakdown

22.8%
§101 Eligibility
12.1%
§102 Novelty
23.5%
§103 Obviousness
31.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17682759 DETERMINING CELL TYPE ORIGIN OF CIRCULATING CELL-FREE DNA WITH MOLECULAR COUNTING Non-Final OA Guardant Health Inc.
17776943 STRUCTURE-BASED DESIGN OF THERAPEUTICS TARGETING RNA HAIRPIN LOOPS Final Rejection The Regents of the University of California
17733762 METHODS FOR DETECTING, MONITORING, AND GUIDING TREATMENT OF ALLOGRAFT REJECTION USING DISCRIMINATING GENE EXPRESSION SIGNATURES Non-Final OA CareDx, Inc.
18404829 METHODS FOR ASSESSING RISK USING TOTAL AND SPECIFIC CELL-FREE DNA Final Rejection The Medical College of Wisconsin, Inc.
17493230 ASSESSING CONDITIONS IN TRANSPLANT SUBJECTS USING DONOR-SPECIFIC CELL-FREE DNA Non-Final OA The Medical College of Wisconsin, Inc.
16623725 TRANSPLANT PATIENT MONITORING WITH CELL-FREE DNA Non-Final OA The Medical College of Wisconsin, Inc.
16623719 ASSESSING CONDITIONS IN TRANSPLANT SUBJECTS USING DONOR-SPECIFIC CELL-FREE DNA Final Rejection The Medical College of Wisconsin, Inc.
17787499 PRIMERS FOR DETECTING TRACE AMOUNT OF RARE SINGLE- NUCLEOTIDE VARIANT AND METHOD FOR SPECIFICALLY AND SENSITIVELY DETECTING TRACE AMOUNT OF RARE SINGLE-NUCLEOTIDE VARIANT BY USING SAME Non-Final OA KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
17433542 MULTIPLEXED SIGNAL AMPLIFICATION METHODS USING ENZYMATIC BASED CHEMICAL DEPOSITION Final Rejection The Board of Trustees of the Leland Stanford Junior University
16809496 METHOD OF IDENTIFYING RISK FOR AUTISM Non-Final OA The Johns Hopkins University
17162718 PREDICTION AND CHARACTERIZATION OF DLBCL CELL OF ORIGIN SUBTYPES Final Rejection Foundation Medicine, Inc.
19088496 METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY Non-Final OA Myriad Genetics, Inc.
17353279 METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY Non-Final OA Myriad Genetics, Inc.
18038915 METHOD FOR DETECTING SEVERITY OF ATOPIC DERMATITIS Non-Final OA KAO CORPORATION
17905129 METHODS OF USING A MULTI-ANALYTE APPROACH FOR DIAGNOSIS AND STAGING A DISEASE Non-Final OA THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
17725341 METHODS FOR DETERMINING VELOCITY OF TUMOR GROWTH Non-Final OA Natera, Inc.
16764496 METHODS TO MEASURE FUNCTIONAL HETEROGENEITY AMONG SINGLE CELLS Final Rejection The Regents of the University of Colorado, a body corporate
18254202 SINGLE NUCLEOTIDE POLYMORPHISM MARKER FOR PREDICTING RISK OF ALZHEIMERS DISEASE AND USE THEREOF Non-Final OA INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHOSUN UNIVERSITY
17931942 SYSTEM AND METHOD FOR TISSUE-WIDE SINGLE CELL POST-TRANSCRIPTIONAL PROFILING OF MULTIPLE MOLECULAR TARGETS Non-Final OA City University of Hong Kong
17429279 COMPOSITIONS AND METHODS FOR CANCER DIAGNOSIS AND PROGNOSIS Non-Final OA King Abdullah University of Science and Technology
17005858 B-CELL MATURATION COMPLEX CAR T CONSTRUCT AND PRIMERS Non-Final OA Janssen Biotech, Inc.
17617183 METHOD OF SIGNAL ENCODING OF ANALYTES IN A SAMPLE Final Rejection RESOLVE BIOSCIENCES GMBH
18448868 METHOD OF TREATMENT WITH TRADIPITANT Final Rejection Vanda Pharmaceuticals Inc.
17652172 METHOD OF POOLING BLOOD SAMPLES Final Rejection Gen-Probe Incorporated
17999616 A GENETIC TEST TO PREDICT ANTI-TNF DRUG RESPONSE Final Rejection University of Ulster
18176152 TESTING ASSAY FOR SCREENING AND DIAGNOSIS OF USHER, PENDRED, JERVELL, AND LANGE-NIELSEN SYNDROMES Non-Final OA Father Flanagan's Boys' Home Doing Business as Boys Town National Research Hospital
18269551 MARKER GENE FOR IDENTIFYING AND CLASSIFYING DPC CELL, SCREENING METHOD THEREFOR AND USE THEREOF Final Rejection IREGENE THERAPEUTICS LTD
17251359 PREDICTIVE 7-GENE ASSAY AND PROGNOSTIC PROTEIN BIOMARKER FOR NON-SMALL CELL LUNG CANCER Final Rejection West Virginia University
18254242 METHOD FOR PREDICTING PATIENT RESPONSE TO CD40-TARGETED THERAPIES Non-Final OA Johannes Gutenberg University (JGU) Medical Center
18036524 NUCLEIC ACID AMPLIFICATION METHOD, PRIMER SET, PROBE, AND KIT FOR NUCLEIC ACID AMPLIFICATION METHOD Non-Final OA EIKEN KAGAKU KABUSHIKI KAISHA

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month